@article {10471, title = {DEFB1 polymorphisms and salivary hBD-1 concentration in Oral Lichen Planus patients and healthy subjects.}, journal = {Arch Oral Biol}, volume = {73}, year = {2017}, month = {2017 Jan}, pages = {161-165}, abstract = {

OBJECTIVES: The aetiology of Oral Lichen Planus (OLP), a chronic inflammatory disease of oral mucosa, is not yet well understood. Since innate immunity may be hypothesized as involved in the susceptibility to OLP, we studied human beta defensin 1 (hBD-1) an antimicrobial peptide constitutively expressed in the saliva, looking at functional genetic variants possibly able to diminish hBD-1 production an consequently conferring major susceptibility to OLP.

DESIGN: We analysed three DEFB1 polymorphisms at 5{\textquoteright} UTR, -52G>A (rs1799946), -44C>G (rs1800972), -20G>A (rs11362) and two DEFB1 polymorphisms at 3{\textquoteright}UTR, c*5G>A (rs1047031), c*87A>G (rs1800971), with the aim of correlating these genetic variants and hBD-1 salivary level in a group of OLP patients and in healthy subjects. We also evaluated hBD-1 salivary concentrations, using ELISA, in OLP and healthy controls.

RESULTS: We compared hBD-1 concentrations in OLP and healthy subjects: hBD-1 concentration was significantly higher in OLP patients respect to control. When considering the correlation between DEFB1 polymorphisms genotypes and hBD-1 expression levels, significant results were obtained for SNPs -52G>A (p=0.03 both in OLP patients and healthy individuals) and -44C>G (p=0.02 in OLP patients).

CONCLUSIONS: hBD-1 production was different between OLP and healthy subjects (not age-matched with OLP). DEFB1 gene polymorphisms, -52G>A and -44C>G, correlated with hBD-1 salivary concentrations.

}, keywords = {5{\textquoteright} Untranslated Regions, Adult, Aged, Aged, 80 and over, beta-Defensins, Female, Genetic Predisposition to Disease, Genotype, Humans, Lichen Planus, Oral, Male, Middle Aged, Polymorphism, Single Nucleotide, Saliva, Sequence Analysis, DNA}, issn = {1879-1506}, doi = {10.1016/j.archoralbio.2016.10.008}, author = {Polesello, Vania and Zupin, Luisa and Di Lenarda, Roberto and Biasotto, Matteo and Pozzato, Gabriele and Ottaviani, Giulia and Gobbo, Margherita and Crovella, Sergio and Segat, Ludovica} } @article {8502, title = {CD209 promoter polymorphisms associate with HCV infection and pegylated-interferon plus ribavirin treatment response.}, journal = {Mol Immunol}, volume = {76}, year = {2016}, month = {2016 Aug}, pages = {49-54}, abstract = {

Hepatitis C is a severe liver disease caused by hepatitis C virus that could persist in the host causing progression towards chronic disease in about 80\% of the cases. Pegylated-interferon plus ribavirin was the gold standard therapy, however treatment{\textquoteright}s response was quite variable among individuals and different host/viral factors may play a role in disease outcome. The cluster of differentiation 209 (CD209 antigen) is a component of the innate immune system able to recognize HCV and consequently activating the immune response. We enrolled 203 Italian HCV infected patients and 220 healthy controls investigating if five promoter polymorphisms within CD209 gene (encoding for CD209 antigen) correlated with HCV infection susceptibility, spontaneous viral clearance and interferon treatment response. CD209 -939G>A and -871A>G polymorphisms associated with HCV infection susceptibility, while, CD209 -871A>G and -336A>G polymorphisms associated with response to treatment. In conclusion, CD209 polymorphisms could play a role in the susceptibility to HCV infection as well as interferon treatment response in our study population from North-East of Italy.

}, issn = {1872-9142}, doi = {10.1016/j.molimm.2016.06.009}, author = {Zupin, Luisa and Polesello, Vania and Alberi, Giulia and Moratelli, Giulia and Croc{\`e}, Saveria Lory and Masutti, Flora and Pozzato, Gabriele and Crovella, Sergio and Segat, Ludovica} } @article {7684, title = {Impact of DEFB1 gene regulatory polymorphisms on hBD-1 salivary concentration.}, journal = {Arch Oral Biol}, volume = {60}, year = {2015}, month = {2015 Jul}, pages = {1054-8}, abstract = {

OBJECTIVES: Human β-defensin 1 (hBD-1) is an antimicrobial peptide involved in epithelial defence of various tissues, also present in the saliva. Individual genetic variations within the DEFB1 gene, encoding for hBD-1, could influence gene expression and protein production.

DESIGN: Three DEFB1 polymorphisms at 5{\textquoteright} untranslated region (UTR), -52G > A (rs1799946), -44C > G (rs1800972) and -20G > A (rs11362), and two polymorphisms at DEFB1 3{\textquoteright} UTR, c*5G > A (rs1047031) and c*87A > G (rs1800971), were analysed by direct sequencing and correlated with hDB-1 salivary concentration (tested with enzyme-linked immunosorbent assay (ELISA)) in 40 healthy subjects.

RESULTS: Significant associations were found between individuals presenting different DEFB1 polymorphisms at positions -52 and -44 of the gene and hBD-1 salivary concentrations: -52 G/G carriers had higher levels of protein than G/A and A/A; -44C/G subjects showed a higher protein concentration than homozygous wild-type C/C. For the -20G > A, c*5G > A and c*87A > G polymorphisms, no statistically significant differences were found. Combined haplotype analysis confirmed the results obtained considering the single-nucleotide polymorphisms (SNPs) singularly.

CONCLUSION: Polymorphisms in the DEFB1 gene influence hBD-1 production and, therefore, could modify the innate immune system responses and, consequently, the oral health.

}, issn = {1879-1506}, doi = {10.1016/j.archoralbio.2015.03.009}, author = {Polesello, Vania and Zupin, Luisa and Di Lenarda, Roberto and Biasotto, Matteo and Ottaviani, Giulia and Gobbo, Margherita and Cecco, Luca and Alberi, Giulia and Pozzato, Gabriele and Crovella, Sergio and Segat, Ludovica} } @article {7725, title = {Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies.}, journal = {Int J Nanomedicine}, volume = {10}, year = {2015}, month = {2015}, pages = {4099-109}, abstract = {

The expectations of nanoparticle (NP)-based targeted drug delivery systems in cancer, when compared with convectional therapeutic methods, are greater efficacy and reduced drug side effects due to specific cellular-level interactions. However, there are conflicting literature reports on enhanced tumor accumulation of targeted NPs, which is essential for translating their applications as improved drug-delivery systems and contrast agents in cancer imaging. In this study, we characterized biodegradable NPs conjugated with an anti-CD20 antibody for in vivo imaging and drug delivery onto tumor cells. NPs{\textquoteright} binding specificity mediated by anti-CD20 antibody was evaluated on MEC1 cells and chronic lymphocytic leukemia patients{\textquoteright} cells. The whole-body distribution of untargeted NPs and anti-CD20 NPs were compared by time-domain optical imaging in a localized human/mouse model of B-cell malignancy. These studies provided evidence that NPs{\textquoteright} functionalization by an anti-CD20 antibody improves tumor pharmacokinetic profiles in vivo after systemic administration and increases in vivo imaging of tumor mass compared to non-targeted NPs. Together, drug delivery and imaging probe represents a promising theranostics tool for targeting B-cell malignancies.

}, issn = {1178-2013}, doi = {10.2147/IJN.S78995}, author = {Capolla, Sara and Garrovo, Chiara and Zorzet, Sonia and Lorenzon, Andrea and Rampazzo, Enrico and Spretz, Ruben and Pozzato, Gabriele and N{\'u}{\~n}ez, Luis and Tripodo, Claudio and Macor, Paolo and Biffi, Stefania} } @article {3483, title = {No evidence of Polyomavirus and EBV infections in Italian patients with mixed cryoglobulinemia infected chronically with HCV.}, journal = {J Med Virol}, volume = {86}, year = {2014}, month = {2014 Apr}, pages = {666-71}, abstract = {

Mixed cryoglobulinemia is a lymphoproliferative disorder associated with hepatitis C virus (HCV). In patients chronically affected by HCV the prevalence of mixed cryoglobulinemia is variable ranging from 0\% to 56\%. To verify whether polyomaviruses (PyV) play a role in this disorder a total of 222 blood samples from 63 HCV chronic patients, 43 with mixed cryoglobulinemia, 59 chronic lymphocytic leukemia, 50 polytransfused patients, and 50 blood donors were evaluated for Merkel (MCPyV), BKV, JCV, and SV40. EBV was additionally included in the analysis since association with this disorder has been reported. Mixed cryoglobulinemia patients infected chronically with HCV resulted negative for both PyV and EBV. MCPyV was found in 1 subject with Merkel Cell Carcinoma, in 10\% of polytransfused and in 10\% of blood donors while EBV was detected in 22\% of polytransfused, 10\% of B-cell lymphatic leukemia patients and 4\% of blood donors (P < 0.01). Taken together, the absence of PyV and EBV in HCV-mixed cryoglobulinemia patients seems to exclude a direct involvement of these viruses in the pathogenesis of this disease while the presence of MCPyV in healthy individuals, at the same rate as in polytransfused patients, may reinforce data on a minimal role of this virus in other human pathologies.

}, keywords = {Adult, Base Sequence, Cryoglobulinemia, DNA, Viral, Epstein-Barr Virus Infections, Female, Hepacivirus, Hepatitis C, Chronic, Herpesvirus 4, Human, Humans, Italy, Leukemia, B-Cell, Male, Middle Aged, Polyomavirus, Polyomavirus Infections, Sequence Analysis, DNA, Vaginal Smears, Young Adult}, issn = {1096-9071}, doi = {10.1002/jmv.23867}, author = {Comar, Manola and Zanotta, Nunzia and Del Savio, Rossella and Vascotto, Fulvia and Calabrese, Nadia and Zorat, Francesca and Pozzato, Gabriele} } @article {1975, title = {Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease.}, journal = {J Clin Virol}, volume = {55}, year = {2012}, month = {2012 Dec}, pages = {367-9}, abstract = {

BACKGROUND: Previous studies have reported conflicting results on the frequency and potential pathogenetic role of Merkel-cell polyomavirus (MCPyV) in B-chronic lymphocytic leukemia (B-CLL).

OBJECTIVES: To evaluate the association of MCPyV to B-CLL and to investigate the occurrence of MCPyV infection in relationship to the natural history of B-CLL.

STUDY DESIGN: Samples of primary B-CLL peripheral blood mononuclear cells were obtained from two distinct University Hospitals of Italy from January 2010. For one B-CLL patient, it was possible to retrospectively examine the blood sample at diagnosis of B-CLL (March 2004) and several pathological tissues of cutaneous tumors occurring during the course of the disease.

RESULTS: Only one out of 50 B-CLL blood samples examined was positive for MCPyV DNA. Retrospective analysis revealed that MCPyV DNA was absent in peripheral blood sample at diagnosis, becoming present only in advanced disease stages also in tonsil tissue as well as in a biopsy of differentiated squamous cell carcinoma.

CONCLUSIONS: The association with MCPyV seems to represent a rare and late event during the natural history of B-CLL.

}, keywords = {Aged, Aged, 80 and over, Blood, Female, Humans, Italy, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Merkel cell polyomavirus, Middle Aged, Palatine Tonsil, Polyomavirus Infections, Prevalence, Skin, Tumor Virus Infections}, issn = {1873-5967}, doi = {10.1016/j.jcv.2012.08.011}, author = {Comar, Manola and Cuneo, Antonio and Maestri, Iva and Melloni, Elisabetta and Pozzato, Gabriele and Soffritti, Olga and Secchiero, Paola and Zauli, Giorgio} }